Lipe & Dalton Takes Position in Eli Lilly and Company (NYSE:LLY)

Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 45 shares of the company’s stock, valued at approximately $26,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after acquiring an additional 659,838 shares in the last quarter. Morgan Stanley increased its position in shares of Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after acquiring an additional 83,915 shares in the last quarter. Northern Trust Corp increased its position in shares of Eli Lilly and Company by 3.6% during the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $3,416,206,000. Finally, International Assets Investment Management LLC increased its position in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LLY. Barclays upped their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. The Goldman Sachs Group upped their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Citigroup upped their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Trading Down 0.6 %

Shares of NYSE LLY traded down $4.21 during midday trading on Tuesday, hitting $746.56. 2,568,597 shares of the company traded hands, compared to its average volume of 3,085,273. Eli Lilly and Company has a 12-month low of $367.35 and a 12-month high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a 50-day moving average price of $762.68 and a 200 day moving average price of $655.54. The firm has a market cap of $709.35 billion, a P/E ratio of 128.34, a P/E/G ratio of 1.65 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the company earned $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 12.46 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.